Global X-Linked Hypophosphatemia Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 1737

X-Linked Hypophosphatemia (XLH) is a genetic disorder characterized by low levels of phosphate in the blood. Phosphate levels in the blood are low as phosphate is abnormally processed in kidneys, which causes a loss of phosphate in urine and leads to soft and weak bones.
Geographically, the Americas is anticipated to dominate the global X-linked hypophosphatemia market owing to a well-developed healthcare sector, rising prevalence of X-linked hypophosphatemia, and growing demand for vitamin supplements. Additionally, the increasing number of patients with genetic disorders, short stature, and growing healthcare expenditure have boosted the growth of the market in the region. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the global X-linked hypophosphatemia market. The market growth in this region is attributed to the growing prevalence of X-linked hypophosphatemia, availability of funds for research, and government support for research and development.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunities in the market. Moreover, increasing investments by market players in this region also contributes to the growth of the market.
In 2018, the global X-Linked Hypophosphatemia market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global X-Linked Hypophosphatemia status, future forecast, growth opportunity, key market and key players. The study objectives are to present the X-Linked Hypophosphatemia development in United States, Europe and China.

The key players covered in this study
Ultragenyx Pharmaceutical
Kyowa Hakko Kirin
Nestle
Merck
Pfizer
Roche
Koninklijke DSM
ADM Alliance Nutrition
Eli Lily
Validus Pharmaceuticals

Market segment by Type, the product can be split into
Medication
Corrective Surgery
Others

Market segment by Application, split into
Hospitals
Clinics
Diagnostic Centers
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global X-Linked Hypophosphatemia status, future forecast, growth opportunity, key market and key players.
To present the X-Linked Hypophosphatemia development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of X-Linked Hypophosphatemia are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global X-Linked Hypophosphatemia Market Size Growth Rate by Type (2014-2025)
1.4.2 Medication
1.4.3 Corrective Surgery
1.4.4 Others
1.5 Market by Application
1.5.1 Global X-Linked Hypophosphatemia Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Diagnostic Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 X-Linked Hypophosphatemia Market Size
2.2 X-Linked Hypophosphatemia Growth Trends by Regions
2.2.1 X-Linked Hypophosphatemia Market Size by Regions (2014-2025)
2.2.2 X-Linked Hypophosphatemia Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 X-Linked Hypophosphatemia Market Size by Manufacturers
3.1.1 Global X-Linked Hypophosphatemia Revenue by Manufacturers (2014-2019)
3.1.2 Global X-Linked Hypophosphatemia Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global X-Linked Hypophosphatemia Market Concentration Ratio (CR5 and HHI)
3.2 X-Linked Hypophosphatemia Key Players Head office and Area Served
3.3 Key Players X-Linked Hypophosphatemia Product/Solution/Service
3.4 Date of Enter into X-Linked Hypophosphatemia Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global X-Linked Hypophosphatemia Market Size by Type (2014-2019)
4.2 Global X-Linked Hypophosphatemia Market Size by Application (2014-2019)

5 United States
5.1 United States X-Linked Hypophosphatemia Market Size (2014-2019)
5.2 X-Linked Hypophosphatemia Key Players in United States
5.3 United States X-Linked Hypophosphatemia Market Size by Type
5.4 United States X-Linked Hypophosphatemia Market Size by Application

6 Europe
6.1 Europe X-Linked Hypophosphatemia Market Size (2014-2019)
6.2 X-Linked Hypophosphatemia Key Players in Europe
6.3 Europe X-Linked Hypophosphatemia Market Size by Type
6.4 Europe X-Linked Hypophosphatemia Market Size by Application

7 China
7.1 China X-Linked Hypophosphatemia Market Size (2014-2019)
7.2 X-Linked Hypophosphatemia Key Players in China
7.3 China X-Linked Hypophosphatemia Market Size by Type
7.4 China X-Linked Hypophosphatemia Market Size by Application

8 Japan
8.1 Japan X-Linked Hypophosphatemia Market Size (2014-2019)
8.2 X-Linked Hypophosphatemia Key Players in Japan
8.3 Japan X-Linked Hypophosphatemia Market Size by Type
8.4 Japan X-Linked Hypophosphatemia Market Size by Application

9 Southeast Asia
9.1 Southeast Asia X-Linked Hypophosphatemia Market Size (2014-2019)
9.2 X-Linked Hypophosphatemia Key Players in Southeast Asia
9.3 Southeast Asia X-Linked Hypophosphatemia Market Size by Type
9.4 Southeast Asia X-Linked Hypophosphatemia Market Size by Application

10 India
10.1 India X-Linked Hypophosphatemia Market Size (2014-2019)
10.2 X-Linked Hypophosphatemia Key Players in India
10.3 India X-Linked Hypophosphatemia Market Size by Type
10.4 India X-Linked Hypophosphatemia Market Size by Application

11 Central & South America
11.1 Central & South America X-Linked Hypophosphatemia Market Size (2014-2019)
11.2 X-Linked Hypophosphatemia Key Players in Central & South America
11.3 Central & South America X-Linked Hypophosphatemia Market Size by Type
11.4 Central & South America X-Linked Hypophosphatemia Market Size by Application

12 International Players Profiles
12.1 Ultragenyx Pharmaceutical
12.1.1 Ultragenyx Pharmaceutical Company Details
12.1.2 Company Description and Business Overview
12.1.3 X-Linked Hypophosphatemia Introduction
12.1.4 Ultragenyx Pharmaceutical Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.1.5 Ultragenyx Pharmaceutical Recent Development
12.2 Kyowa Hakko Kirin
12.2.1 Kyowa Hakko Kirin Company Details
12.2.2 Company Description and Business Overview
12.2.3 X-Linked Hypophosphatemia Introduction
12.2.4 Kyowa Hakko Kirin Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.2.5 Kyowa Hakko Kirin Recent Development
12.3 Nestle
12.3.1 Nestle Company Details
12.3.2 Company Description and Business Overview
12.3.3 X-Linked Hypophosphatemia Introduction
12.3.4 Nestle Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.3.5 Nestle Recent Development
12.4 Merck
12.4.1 Merck Company Details
12.4.2 Company Description and Business Overview
12.4.3 X-Linked Hypophosphatemia Introduction
12.4.4 Merck Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.4.5 Merck Recent Development
12.5 Pfizer
12.5.1 Pfizer Company Details
12.5.2 Company Description and Business Overview
12.5.3 X-Linked Hypophosphatemia Introduction
12.5.4 Pfizer Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.5.5 Pfizer Recent Development
12.6 Roche
12.6.1 Roche Company Details
12.6.2 Company Description and Business Overview
12.6.3 X-Linked Hypophosphatemia Introduction
12.6.4 Roche Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.6.5 Roche Recent Development
12.7 Koninklijke DSM
12.7.1 Koninklijke DSM Company Details
12.7.2 Company Description and Business Overview
12.7.3 X-Linked Hypophosphatemia Introduction
12.7.4 Koninklijke DSM Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.7.5 Koninklijke DSM Recent Development
12.8 ADM Alliance Nutrition
12.8.1 ADM Alliance Nutrition Company Details
12.8.2 Company Description and Business Overview
12.8.3 X-Linked Hypophosphatemia Introduction
12.8.4 ADM Alliance Nutrition Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.8.5 ADM Alliance Nutrition Recent Development
12.9 Eli Lily
12.9.1 Eli Lily Company Details
12.9.2 Company Description and Business Overview
12.9.3 X-Linked Hypophosphatemia Introduction
12.9.4 Eli Lily Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.9.5 Eli Lily Recent Development
12.10 Validus Pharmaceuticals
12.10.1 Validus Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 X-Linked Hypophosphatemia Introduction
12.10.4 Validus Pharmaceuticals Revenue in X-Linked Hypophosphatemia Business (2014-2019)
12.10.5 Validus Pharmaceuticals Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details